Published in Proc Natl Acad Sci U S A on August 04, 2006
Microenvironmental regulation of metastasis. Nat Rev Cancer (2008) 15.76
Matrix metalloproteinases: regulators of the tumor microenvironment. Cell (2010) 12.90
Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol (2012) 12.19
Tumor angiogenesis. N Engl J Med (2008) 11.30
Polarization of tumor-associated neutrophil phenotype by TGF-beta: "N1" versus "N2" TAN. Cancer Cell (2009) 8.21
HIF1alpha induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasion. Cancer Cell (2008) 8.01
Neutrophils in the activation and regulation of innate and adaptive immunity. Nat Rev Immunol (2011) 6.96
Eicosanoids and cancer. Nat Rev Cancer (2010) 5.96
Blocking TNF-alpha in mice reduces colorectal carcinogenesis associated with chronic colitis. J Clin Invest (2008) 5.26
Tumors as organs: complex tissues that interface with the entire organism. Dev Cell (2010) 3.98
Chemotaxis in cancer. Nat Rev Cancer (2011) 3.68
The polarization of immune cells in the tumour environment by TGFbeta. Nat Rev Immunol (2010) 3.57
Endothelial progenitor cells: identity defined? J Cell Mol Med (2009) 2.96
Tumor entrained neutrophils inhibit seeding in the premetastatic lung. Cancer Cell (2011) 2.96
Bone marrow-derived endothelial progenitor cells are a major determinant of nascent tumor neovascularization. Genes Dev (2007) 2.60
Neutrophil elastase-mediated degradation of IRS-1 accelerates lung tumor growth. Nat Med (2010) 2.44
Interactions between lymphocytes and myeloid cells regulate pro- versus anti-tumor immunity. Cancer Metastasis Rev (2010) 2.41
MicroRNA dynamics in the stages of tumorigenesis correlate with hallmark capabilities of cancer. Genes Dev (2009) 2.41
Visualizing stromal cell dynamics in different tumor microenvironments by spinning disk confocal microscopy. Dis Model Mech (2008) 2.34
Role of Bv8 in neutrophil-dependent angiogenesis in a transgenic model of cancer progression. Proc Natl Acad Sci U S A (2008) 2.30
Mechanistic links between COPD and lung cancer. Nat Rev Cancer (2013) 2.28
Human neutrophils uniquely release TIMP-free MMP-9 to provide a potent catalytic stimulator of angiogenesis. Proc Natl Acad Sci U S A (2007) 2.27
Inhibition of Mac-1 (CD11b/CD18) enhances tumor response to radiation by reducing myeloid cell recruitment. Proc Natl Acad Sci U S A (2010) 2.19
Endogenous Myc maintains the tumor microenvironment. Genes Dev (2011) 2.16
The multifaceted functions of neutrophils. Annu Rev Pathol (2013) 1.97
Neutrophils responsive to endogenous IFN-beta regulate tumor angiogenesis and growth in a mouse tumor model. J Clin Invest (2010) 1.96
VEGF-A recruits a proangiogenic MMP-9-delivering neutrophil subset that induces angiogenesis in transplanted hypoxic tissue. Blood (2012) 1.94
Effect of ablation or inhibition of stromal matrix metalloproteinase-9 on lung metastasis in a breast cancer model is dependent on genetic background. Cancer Res (2008) 1.88
Leukocytes in mammary development and cancer. Cold Spring Harb Perspect Biol (2011) 1.88
Origins of the tumor microenvironment: quantitative assessment of adipose-derived and bone marrow-derived stroma. PLoS One (2012) 1.82
Plasticity in tumor-promoting inflammation: impairment of macrophage recruitment evokes a compensatory neutrophil response. Neoplasia (2008) 1.70
Toll-like receptor 5 engagement modulates tumor development and growth in a mouse xenograft model of human colon cancer. Gastroenterology (2008) 1.70
Elusive identities and overlapping phenotypes of proangiogenic myeloid cells in tumors. Am J Pathol (2010) 1.70
Chemokines in tumor progression and metastasis. Oncotarget (2013) 1.64
Bone marrow-derived endothelial progenitor cells contribute to the angiogenic switch in tumor growth and metastatic progression. Biochim Biophys Acta (2009) 1.54
Id1 restrains p21 expression to control endothelial progenitor cell formation. PLoS One (2007) 1.52
Pleiotropic roles of matrix metalloproteinases in tumor angiogenesis: contrasting, overlapping and compensatory functions. Biochim Biophys Acta (2009) 1.46
Neutrophils: key mediators of tumour angiogenesis. Int J Exp Pathol (2009) 1.41
Transcriptomic analysis comparing tumor-associated neutrophils with granulocytic myeloid-derived suppressor cells and normal neutrophils. PLoS One (2012) 1.40
The metastasis-promoting roles of tumor-associated immune cells. J Mol Med (Berl) (2013) 1.40
Tumor endothelial cells. Cold Spring Harb Perspect Med (2012) 1.39
Tumor-recruited neutrophils and neutrophil TIMP-free MMP-9 regulate coordinately the levels of tumor angiogenesis and efficiency of malignant cell intravasation. Am J Pathol (2011) 1.37
Granulocyte colony-stimulating factor enhances bone tumor growth in mice in an osteoclast-dependent manner. Blood (2006) 1.35
Can neutrophil-to-lymphocyte ratio predict the survival of colorectal cancer patients who have received curative surgery electively? Int J Colorectal Dis (2012) 1.34
Tumor-associated neutrophils stimulate T cell responses in early-stage human lung cancer. J Clin Invest (2014) 1.33
Up for Mischief? IL-17/Th17 in the tumour microenvironment. Oncogene (2010) 1.32
Role of endothelial progenitors and other bone marrow-derived cells in the development of the tumor vasculature. Angiogenesis (2009) 1.31
Activation of Toll-like receptor 5 on breast cancer cells by flagellin suppresses cell proliferation and tumor growth. Cancer Res (2011) 1.30
Systemic inflammatory status at baseline predicts bevacizumab benefit in advanced non-small cell lung cancer patients. Cancer Biol Ther (2013) 1.26
Immunological hallmarks of stromal cells in the tumour microenvironment. Nat Rev Immunol (2015) 1.24
The Multifaceted Roles Neutrophils Play in the Tumor Microenvironment. Cancer Microenviron (2014) 1.24
Twist1 induces CCL2 and recruits macrophages to promote angiogenesis. Cancer Res (2013) 1.24
M402, a novel heparan sulfate mimetic, targets multiple pathways implicated in tumor progression and metastasis. PLoS One (2011) 1.24
Neutrophils in innate and adaptive immunity. Semin Immunopathol (2013) 1.23
The tumor microenvironment in colorectal carcinogenesis. Cancer Microenviron (2010) 1.23
Myeloid cells contribute to tumor lymphangiogenesis. PLoS One (2009) 1.22
The impact of the immune system on tumor: angiogenesis and vascular remodeling. Front Oncol (2014) 1.22
Clinical and experimental pancreatic islet transplantation to striated muscle: establishment of a vascular system similar to that in native islets. Diabetes (2010) 1.20
Invasive breast cancer reprograms early myeloid differentiation in the bone marrow to generate immunosuppressive neutrophils. Proc Natl Acad Sci U S A (2015) 1.17
Protumor and antitumor functions of neutrophil granulocytes. Semin Immunopathol (2012) 1.17
Crucial involvement of tumor-associated neutrophils in the regulation of chronic colitis-associated carcinogenesis in mice. PLoS One (2012) 1.17
Inducible cutaneous inflammation reveals a protumorigenic role for keratinocyte CXCR2 in skin carcinogenesis. Cancer Res (2009) 1.17
Targeting CXCL12/CXCR4 signaling with oncolytic virotherapy disrupts tumor vasculature and inhibits breast cancer metastases. Proc Natl Acad Sci U S A (2013) 1.17
Spatial and temporal coordination of bone marrow-derived cell activity during arteriogenesis: regulation of the endogenous response and therapeutic implications. Microcirculation (2010) 1.15
Tumor angiogenesis: MMP-mediated induction of intravasation- and metastasis-sustaining neovasculature. Matrix Biol (2015) 1.15
Targeting vascular and leukocyte communication in angiogenesis, inflammation and fibrosis. Nat Rev Drug Discov (2015) 1.14
Neutrophil MMP-9 proenzyme, unencumbered by TIMP-1, undergoes efficient activation in vivo and catalytically induces angiogenesis via a basic fibroblast growth factor (FGF-2)/FGFR-2 pathway. J Biol Chem (2009) 1.14
Tumor engineering: the other face of tissue engineering. Tissue Eng Part A (2010) 1.12
Semaphorin 3A overcomes cancer hypoxia and metastatic dissemination induced by antiangiogenic treatment in mice. J Clin Invest (2012) 1.11
Gelatinase B/MMP-9 in Tumour Pathogenesis and Progression. Cancers (Basel) (2014) 1.10
Myeloid cell trafficking and tumor angiogenesis. Cancer Lett (2006) 1.10
Angiopoietin-2 in experimental colitis. Inflamm Bowel Dis (2010) 1.10
Suppressive effects of vascular endothelial growth factor-B on tumor growth in a mouse model of pancreatic neuroendocrine tumorigenesis. PLoS One (2010) 1.09
Forced expression of MMP9 rescues the loss of angiogenesis and abrogates metastasis of pancreatic tumors triggered by the absence of host SPARC. Exp Biol Med (Maywood) (2008) 1.08
Bone marrow is a reservoir for proangiogenic myelomonocytic cells but not endothelial cells in spontaneous tumors. Blood (2010) 1.08
Ocular neovascularization caused by herpes simplex virus type 1 infection results from breakdown of binding between vascular endothelial growth factor A and its soluble receptor. J Immunol (2011) 1.07
The prognostic value of tumor-infiltrating neutrophils in gastric adenocarcinoma after resection. PLoS One (2012) 1.06
Development of a syngeneic mouse model of epithelial ovarian cancer. J Ovarian Res (2010) 1.06
Neutrophils in cancer: neutral no more. Nat Rev Cancer (2016) 1.06
The oxysterol-CXCR2 axis plays a key role in the recruitment of tumor-promoting neutrophils. J Exp Med (2013) 1.06
Extracellular regulation of VEGF: isoforms, proteolysis, and vascular patterning. Cytokine Growth Factor Rev (2013) 1.05
Bone marrow microenvironment and tumor progression. Cancer Microenviron (2008) 1.04
Angiogenic capacity of M1- and M2-polarized macrophages is determined by the levels of TIMP-1 complexed with their secreted proMMP-9. Blood (2013) 1.03
Genetic and pharmacologic inhibition of complement impairs endothelial cell function and ablates ovarian cancer neovascularization. Neoplasia (2012) 1.02
Matrix metalloproteinase-9 contributes to intestinal tumourigenesis in the adenomatous polyposis coli multiple intestinal neoplasia mouse. Int J Exp Pathol (2008) 1.02
Tumor-stromal interactions in pancreatic cancer. Crit Rev Oncog (2013) 1.01
FTY720 suppresses liver tumor metastasis by reducing the population of circulating endothelial progenitor cells. PLoS One (2012) 1.01
Complex role for the immune system in initiation and progression of pancreatic cancer. World J Gastroenterol (2014) 1.00
Using the transcription factor inhibitor of DNA binding 1 to selectively target endothelial progenitor cells offers novel strategies to inhibit tumor angiogenesis and growth. Cancer Res (2010) 1.00
Pre-treatment neutrophil-to-lymphocyte ratio is associated with neutrophil and T-cell infiltration and predicts clinical outcome in patients with glioblastoma. BMC Cancer (2015) 1.00
Tissue-infiltrating neutrophils constitute the major in vivo source of angiogenesis-inducing MMP-9 in the tumor microenvironment. Neoplasia (2014) 0.99
Critical roles for macrophages in islet angiogenesis and maintenance during pancreatic degeneration. Diabetes (2008) 0.99
Pathobiology of the neutrophil-intestinal epithelial cell interaction: role in carcinogenesis. World J Gastroenterol (2010) 0.99
Opposing roles for complement component C5a in tumor progression and the tumor microenvironment. J Immunol (2012) 0.98
Macrophages and chemokines as mediators of angiogenesis. Front Physiol (2013) 0.98
Balancing the innate immune system in tumor development. Trends Cell Biol (2014) 0.98
Identification and characterization of VEGF-A-responsive neutrophils expressing CD49d, VEGFR1, and CXCR4 in mice and humans. Blood (2015) 0.98
Gut bacteria require neutrophils to promote mammary tumorigenesis. Oncotarget (2015) 0.97
A digest on the role of the tumor microenvironment in gastrointestinal cancers. Cancer Microenviron (2010) 0.97
Orchestration of angiogenesis by immune cells. Front Oncol (2014) 0.97
Inflammation and cancer. Nature (2002) 53.78
Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell (1996) 23.99
Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol (2002) 17.85
Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer (2004) 14.55
Liposome mediated depletion of macrophages: mechanism of action, preparation of liposomes and applications. J Immunol Methods (1994) 13.53
Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol (2000) 13.29
Heritable formation of pancreatic beta-cell tumours in transgenic mice expressing recombinant insulin/simian virus 40 oncogenes. Nature (1985) 9.78
The immunobiology of cancer immunosurveillance and immunoediting. Immunity (2004) 9.39
Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell (2005) 9.18
The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies. J Pathol (2002) 8.27
MMP-9 supplied by bone marrow-derived cells contributes to skin carcinogenesis. Cell (2000) 8.00
Expansion of myeloid immune suppressor Gr+CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis. Cancer Cell (2004) 7.61
Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature (1989) 7.30
Inflammatory mast cells up-regulate angiogenesis during squamous epithelial carcinogenesis. Genes Dev (1999) 6.10
De novo carcinogenesis promoted by chronic inflammation is B lymphocyte dependent. Cancer Cell (2005) 5.79
Effects of angiogenesis inhibitors on multistage carcinogenesis in mice. Science (1999) 4.91
Cathepsin cysteine proteases are effectors of invasive growth and angiogenesis during multistage tumorigenesis. Cancer Cell (2004) 4.38
An amino-bisphosphonate targets MMP-9-expressing macrophages and angiogenesis to impair cervical carcinogenesis. J Clin Invest (2004) 4.03
VEGF-A has a critical, nonredundant role in angiogenic switching and pancreatic beta cell carcinogenesis. Cancer Cell (2002) 3.27
The intriguing role of polymorphonuclear neutrophils in antitumor reactions. Blood (2001) 2.92
Non-tolerance and autoantibodies to a transgenic self antigen expressed in pancreatic beta cells. Nature (1987) 2.90
Caveolin-1 gene disruption promotes mammary tumorigenesis and dramatically enhances lung metastasis in vivo. Role of Cav-1 in cell invasiveness and matrix metalloproteinase (MMP-2/9) secretion. J Biol Chem (2004) 2.37
Tumour-associated macrophages as a prototypic type II polarised phagocyte population: role in tumour progression. Eur J Cancer (2004) 2.12
Role of infiltrated leucocytes in tumour growth and spread. Br J Cancer (2004) 1.98
Polymorphic expression of a neutrophil differentiation antigen revealed by monoclonal antibody 7/4. Immunogenetics (1983) 1.96
Activation of progelatinase A (MMP-2) by neutrophil elastase, cathepsin G, and proteinase-3: a role for inflammatory cells in tumor invasion and angiogenesis. J Cell Physiol (2001) 1.88
Immune enhancement of skin carcinogenesis by CD4+ T cells. J Exp Med (2003) 1.84
Infiltration of neutrophils is required for acquisition of metastatic phenotype of benign murine fibrosarcoma cells: implication of inflammation-associated carcinogenesis and tumor progression. Am J Pathol (2003) 1.75
Granulocyte colony-stimulating factor promotes tumor angiogenesis via increasing circulating endothelial progenitor cells and Gr1+CD11b+ cells in cancer animal models. Int Immunol (2005) 1.75
Tumor-elicited polymorphonuclear cells, in contrast to "normal" circulating polymorphonuclear cells, stimulate invasive and metastatic potentials of rat mammary adenocarcinoma cells. Proc Natl Acad Sci U S A (1989) 1.68
Differential response of primary and metastatic melanomas to neutrophils attracted by IL-8. Int J Cancer (2003) 1.62
Granulocyte colony-stimulating factor promotes neovascularization by releasing vascular endothelial growth factor from neutrophils. FASEB J (2005) 1.56
CD4+ T cell-mediated antigen-specific immunotherapy in a mouse model of cervical cancer. Cancer Res (2005) 1.44
Ets2-dependent stromal regulation of mouse mammary tumors. Mol Cell Biol (2003) 1.43
A functional heparan sulfate mimetic implicates both heparanase and heparan sulfate in tumor angiogenesis and invasion in a mouse model of multistage cancer. Oncogene (2005) 1.43
Clodronate liposomes: perspectives in research and therapeutics. J Liposome Res (2003) 1.34
Generation of biologically active angiostatin kringle 1-3 by activated human neutrophils. J Immunol (2002) 1.28
Treatment of mice with the neutrophil-depleting antibody RB6-8C5 results in early development of experimental lyme arthritis via the recruitment of Gr-1- polymorphonuclear leukocyte-like cells. Infect Immun (2004) 1.10
Elastase expression by infiltrating neutrophils in gliomas. Neurol Res (2000) 0.97
Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell (2009) 16.06
Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer (2008) 15.20
Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell (2005) 9.18
Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest (2003) 8.34
Cancer-Associated Fibroblasts Are Activated in Incipient Neoplasia to Orchestrate Tumor-Promoting Inflammation in an NF-kappaB-Dependent Manner. Cancer Cell (2010) 6.33
A colorectal cancer classification system that associates cellular phenotype and responses to therapy. Nat Med (2013) 6.09
Both p16(Ink4a) and the p19(Arf)-p53 pathway constrain progression of pancreatic adenocarcinoma in the mouse. Proc Natl Acad Sci U S A (2006) 5.90
Smad4 is dispensable for normal pancreas development yet critical in progression and tumor biology of pancreas cancer. Genes Dev (2006) 5.53
Cathepsin cysteine proteases are effectors of invasive growth and angiogenesis during multistage tumorigenesis. Cancer Cell (2004) 4.38
GLI1 is regulated through Smoothened-independent mechanisms in neoplastic pancreatic ducts and mediates PDAC cell survival and transformation. Genes Dev (2009) 4.21
Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy. Nat Med (2011) 4.10
An amino-bisphosphonate targets MMP-9-expressing macrophages and angiogenesis to impair cervical carcinogenesis. J Clin Invest (2004) 4.03
Tissue-penetrating delivery of compounds and nanoparticles into tumors. Cancer Cell (2009) 4.02
A multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer. J Clin Oncol (2004) 3.40
VEGF-A has a critical, nonredundant role in angiogenic switching and pancreatic beta cell carcinogenesis. Cancer Cell (2002) 3.27
Pandemic H1N1 influenza vaccine induces a recall response in humans that favors broadly cross-reactive memory B cells. Proc Natl Acad Sci U S A (2012) 3.27
Insulin receptor functionally enhances multistage tumor progression and conveys intrinsic resistance to IGF-1R targeted therapy. Proc Natl Acad Sci U S A (2010) 3.16
Elevated levels of IGF-1 receptor convey invasive and metastatic capability in a mouse model of pancreatic islet tumorigenesis. Cancer Cell (2002) 3.02
Distinct roles for cysteine cathepsin genes in multistage tumorigenesis. Genes Dev (2006) 2.74
Antitumor effects in mice of low-dose (metronomic) cyclophosphamide administered continuously through the drinking water. Cancer Res (2002) 2.69
Stage-specific vascular markers revealed by phage display in a mouse model of pancreatic islet tumorigenesis. Cancer Cell (2003) 2.56
MicroRNA dynamics in the stages of tumorigenesis correlate with hallmark capabilities of cancer. Genes Dev (2009) 2.41
Functions of paracrine PDGF signaling in the proangiogenic tumor stroma revealed by pharmacological targeting. PLoS Med (2008) 2.40
Endogenous Myc maintains the tumor microenvironment. Genes Dev (2011) 2.16
Of mice and MEN1: Insulinomas in a conditional mouse knockout. Mol Cell Biol (2003) 2.12
Transformation-associated changes in sphingolipid metabolism sensitize cells to lysosomal cell death induced by inhibitors of acid sphingomyelinase. Cancer Cell (2013) 2.09
Progressive vascular changes in a transgenic mouse model of squamous cell carcinoma. Cancer Cell (2003) 2.07
Brivanib, a dual FGF/VEGF inhibitor, is active both first and second line against mouse pancreatic neuroendocrine tumors developing adaptive/evasive resistance to VEGF inhibition. Clin Cancer Res (2011) 1.85
Immune enhancement of skin carcinogenesis by CD4+ T cells. J Exp Med (2003) 1.84
Plasticity in tumor-promoting inflammation: impairment of macrophage recruitment evokes a compensatory neutrophil response. Neoplasia (2008) 1.70
Pericytes promote endothelial cell survival through induction of autocrine VEGF-A signaling and Bcl-w expression. Blood (2011) 1.66
Impaired Antibody-mediated Protection and Defective IgA B-Cell Memory in Experimental Infection of Adults with Respiratory Syncytial Virus. Am J Respir Crit Care Med (2015) 1.65
A CCR4 antagonist combined with vaccines induces antigen-specific CD8+ T cells and tumor immunity against self antigens. Blood (2011) 1.51
CD4+ T cell-mediated antigen-specific immunotherapy in a mouse model of cervical cancer. Cancer Res (2005) 1.44
A functional heparan sulfate mimetic implicates both heparanase and heparan sulfate in tumor angiogenesis and invasion in a mouse model of multistage cancer. Oncogene (2005) 1.43
Multiple roles for cysteine cathepsins in cancer. Cell Cycle (2004) 1.36
Enhancing tumor-specific uptake of the anticancer drug cisplatin with a copper chelator. Cancer Cell (2010) 1.35
Direct test of potential roles of EIIIA and EIIIB alternatively spliced segments of fibronectin in physiological and tumor angiogenesis. Mol Cell Biol (2004) 1.34
Translational medicine: Cancer lessons from mice to humans. Nature (2011) 1.26
Imaging guided trials of the angiogenesis inhibitor sunitinib in mouse models predict efficacy in pancreatic neuroendocrine but not ductal carcinoma. Proc Natl Acad Sci U S A (2011) 1.26
Inhibition of cysteine cathepsin protease activity enhances chemotherapy regimens by decreasing tumor growth and invasiveness in a mouse model of multistage cancer. Cancer Res (2007) 1.24
The biology of personalized cancer medicine: facing individual complexities underlying hallmark capabilities. Mol Oncol (2012) 1.21
Lymphatic zip codes in premalignant lesions and tumors. Cancer Res (2006) 1.18
Cancer. Breaching the cancer fortress. Science (2009) 1.15
Sub-lethal radiation enhances anti-tumor immunotherapy in a transgenic mouse model of pancreatic cancer. BMC Cancer (2002) 1.14
Counterbalancing angiogenic regulatory factors control the rate of cancer progression and survival in a stage-specific manner. Proc Natl Acad Sci U S A (2011) 1.13
Assessing tumor progression factors by somatic gene transfer into a mouse model: Bcl-xL promotes islet tumor cell invasion. PLoS Biol (2007) 1.13
Protective and dysregulated T cell immunity in RSV infection. Curr Opin Virol (2013) 1.08
Bioavailable copper modulates oxidative phosphorylation and growth of tumors. Proc Natl Acad Sci U S A (2013) 1.06
Incomplete inhibition of the Rb tumor suppressor pathway in the context of inactivated p53 is sufficient for pancreatic islet tumorigenesis. Oncogene (2005) 1.02
Increased vascular delivery and efficacy of chemotherapy after inhibition of platelet-derived growth factor-B. Am J Pathol (2011) 0.99
Hijacking the neuronal NMDAR signaling circuit to promote tumor growth and invasion. Cell (2013) 0.98
Oncogene expression and genetic background influence the frequency of DNA copy number abnormalities in mouse pancreatic islet cell carcinomas. Cancer Res (2004) 0.97
Genetic deletion of the desmosomal component desmoplakin promotes tumor microinvasion in a mouse model of pancreatic neuroendocrine carcinogenesis. PLoS Genet (2010) 0.96
Dendritic cells in human thymus and periphery display a proinsulin epitope in a transcription-dependent, capture-independent fashion. J Immunol (2005) 0.95
Current concepts and progress in RSV vaccine development. Expert Rev Vaccines (2014) 0.95
Differential contribution to neuroendocrine tumorigenesis of parallel egfr signaling in cancer cells and pericytes. Genes Cancer (2010) 0.90
Loss of p19(Arf) facilitates the angiogenic switch and tumor initiation in a multi-stage cancer model via p53-dependent and independent mechanisms. PLoS One (2010) 0.88
A biocompatible in vivo ligation reaction and its application for noninvasive bioluminescent imaging of protease activity in living mice. ACS Chem Biol (2013) 0.88
gp120-Independent infection of CD4(-) epithelial cells and CD4(+) T-cells by HIV-1. J Acquir Immune Defic Syndr (2002) 0.88
A single-chain H-2Db molecule presenting an influenza virus nucleoprotein epitope shows enhanced ability at stimulating CD8+ T cell responses in vivo. J Immunol (2009) 0.87
Targeting cathepsin E in pancreatic cancer by a small molecule allows in vivo detection. Neoplasia (2013) 0.83
Genetic ablation of Bcl-x attenuates invasiveness without affecting apoptosis or tumor growth in a mouse model of pancreatic neuroendocrine cancer. PLoS One (2009) 0.83
Report from the society for biological therapy and vascular biology faculty of the NCI workshop on angiogenesis monitoring. J Immunother (2004) 0.82
Using a preclinical mouse model of high-grade astrocytoma to optimize p53 restoration therapy. Proc Natl Acad Sci U S A (2013) 0.82
Polymorphic genetic control of tumor invasion in a mouse model of pancreatic neuroendocrine carcinogenesis. Proc Natl Acad Sci U S A (2010) 0.82
Absence of telomerase and shortened telomeres have minimal effects on skin and pancreatic carcinogenesis elicited by viral oncogenes. Cancer Cell (2004) 0.78
A new twist on radiation oncology: low-dose irradiation elicits immunostimulatory macrophages that unlock barriers to tumor immunotherapy. Cancer Cell (2013) 0.78
Identification and characterization of poorly differentiated invasive carcinomas in a mouse model of pancreatic neuroendocrine tumorigenesis. PLoS One (2013) 0.77
Randomized control trial of computer-based rehabilitation of spatial neglect syndrome: the RESPONSE trial protocol. BMC Neurol (2014) 0.75
Erratum: RSV-specific airway resident memory CD8+ T cells and differential disease severity after experimental human infection. Nat Commun (2016) 0.75
Wanted: cancer boss. Nature (2006) 0.75
Procathepsin E is highly abundant but minimally active in pancreatic ductal adenocarcinoma tumors. Biol Chem (2016) 0.75